Last reviewed · How we verify
TDM-based infliximab intravenous therapy
Infliximab is a TNF-alpha inhibitor monoclonal antibody that binds and neutralizes tumor necrosis factor-alpha, reducing inflammatory responses in autoimmune and inflammatory diseases.
Infliximab is a TNF-alpha inhibitor monoclonal antibody that binds and neutralizes tumor necrosis factor-alpha, reducing inflammatory responses in autoimmune and inflammatory diseases. Used for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.
At a glance
| Generic name | TDM-based infliximab intravenous therapy |
|---|---|
| Also known as | TDM-based infliximab (CT-P13, RemsimaTM) intravenous therapy |
| Sponsor | Asan Medical Center |
| Drug class | TNF-alpha inhibitor |
| Target | TNF-alpha (Tumor Necrosis Factor-alpha) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Infliximab is a chimeric monoclonal antibody that specifically targets and blocks TNF-alpha, a key pro-inflammatory cytokine. By neutralizing TNF-alpha, it suppresses the inflammatory cascade and reduces immune-mediated tissue damage. TDM-based (therapeutic drug monitoring) dosing optimizes infliximab exposure to maintain therapeutic levels while minimizing immunogenicity and adverse effects.
Approved indications
- Rheumatoid arthritis
- Crohn's disease
- Ulcerative colitis
- Ankylosing spondylitis
- Psoriasis
- Psoriatic arthritis
Common side effects
- Infections (including tuberculosis, fungal, and opportunistic)
- Infusion reactions
- Headache
- Fatigue
- Nausea
- Increased liver enzymes
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: